103 filings
ARS
2023 FY
TRML
Tourmaline Bio Inc
19 Apr 24
Annual report to shareholders
4:05pm
DEFA14A
TRML
Tourmaline Bio Inc
19 Apr 24
Additional proxy soliciting materials
4:04pm
DEF 14A
TRML
Tourmaline Bio Inc
Definitive proxy
19 Apr 24
4:02pm
S-8
TRML
Tourmaline Bio Inc
19 Mar 24
Registration of securities for employees
5:10pm
10-K
2023 FY
TRML
Tourmaline Bio Inc
Annual report
19 Mar 24
5:02pm
8-K
9uzj8xw7vlg0x ih
19 Mar 24
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:09am
8-K
riliof0g
26 Jan 24
Other Events
4:12pm
424B5
9gg1scc
26 Jan 24
Prospectus supplement for primary offering
4:08pm
424B5
qta7zrq8os
24 Jan 24
Prospectus supplement for primary offering
9:20pm
8-K
ptj84aih4i
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
ufkw4 12y3xi0
8 Jan 24
Regulation FD Disclosure
9:19am
8-K
dnw39wmptrw
14 Dec 23
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
8:27am
8-K
14753t 5qx57
30 Nov 23
Departure of Directors or Certain Officers
8:25am
8-K
5izlfh8up tb5
14 Nov 23
Index to Unaudited Condensed Financial Statements
5:15pm
8-K
x9rlnxmnlj9tipd
27 Oct 23
Departure of Directors or Certain Officers
5:17pm
S-8
52162y
20 Oct 23
Registration of securities for employees
9:23pm
8-K
d3iyb4f 7jyn
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
smv35l8e u6
17 Oct 23
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
6:35pm
425
gfo93ln7u
10 Oct 23
Business combination disclosure
4:32pm